Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.69 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.57 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.57 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517652 | 0.80 | EGLN3 (0.55) | EGLN1EGLN3FTOEGLN2KDM5B | |
| SCHEMBL31057838 | 0.79 | ALDH1A1 (0.60) | EGLN1FTOKDM2AKDM4CALDH1A1 | |
| SCHEMBL16040593 | 0.79 | ALDH1A1 (0.60) | EGLN1FTOKDM2AKDM4CALDH1A1 | |
| SCHEMBL7382937 | 0.78 | EGLN1 (0.74) | EGLN1FTOEGLN2ALDH1A1MAPT | |
| SCHEMBL3396850 | 0.78 | EGLN3 (1.00) | EGLN1EGLN3FTOKDM5BKDM2A | |
| SCHEMBL3393384 | 0.77 | EGLN3 (0.70) | EGLN1EGLN3FTOEGLN2KDM5B | |
| SCHEMBL1081723 | 0.75 | EGLN1 (0.61) | EGLN1EGLN3FTOEGLN2KDM5B | |
| SCHEMBL3758723 | 0.74 | EGLN3 (0.56) | EGLN1EGLN3FTOEGLN2KDM5B | |
| SCHEMBL31022679 | 0.74 | ERN1 (0.54) | EGLN1FTOKDM2AKDM4CALDH1A1 | |
| SCHEMBL3518993 | 0.74 | EGLN3 (0.60) | EGLN1EGLN3FTOEGLN2KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101932324-A | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC | 2010-12-29 | — | — | CN | claimed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | claimed |
| EP-2224926-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | claimed |
| CN-101932324-A | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC | 2010-12-29 | — | — | CN | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| EP-2224926-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885EGLN3 2/4885FTO 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.